Core Viewpoint - The company is utilizing idle raised funds for cash management through low-risk structured deposits to enhance fund efficiency and shareholder returns [1][3]. Cash Management Overview - Cash management type: Structured deposits from Zheshang Bank [1][2] - Cash management amount: 40 million RMB [2] - Source of cash management: Proceeds from the issuance of convertible bonds [2] - Cash management purpose: To improve the efficiency of idle funds, reduce financial costs, and increase shareholder returns while ensuring normal operations and project construction [1][3]. Cash Management Details - The company has approved the use of up to 300 million RMB of idle raised funds for cash management, with a specific investment of 40 million RMB in structured deposits [4][5]. - The structured deposit has a term of 61 days, with expected annualized returns ranging from 1.00% to 2.45% [2][4]. - As of the announcement date, the remaining balance of idle funds in cash management is 205 million RMB [4]. Approval Process - The cash management proposal was approved during the board and supervisory meetings held on April 18, 2025, and was subsequently ratified by the annual shareholders' meeting [4][5]. Risk Management - The structured deposit is considered low-risk and liquid, with a commitment to capital preservation, ensuring compliance with fund management requirements [3][5]. - The company will conduct regular audits and assessments of the investment products to manage risks effectively [5]. Impact on the Company - The cash management initiative is designed to enhance fund utilization efficiency and generate returns for the company and its shareholders without affecting the construction of fundraising projects [5].

Core Viewpoint - Zhejiang Shouxiangu Pharmaceutical Co., Ltd. will hold a performance briefing for the first half of 2025 on September 12, 2025, to provide investors with insights into the company's operational results and financial status [1][2]. Group 1: Meeting Details - The performance briefing is scheduled for September 12, 2025, from 13:00 to 14:30 [1][2]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will utilize a video recording combined with online interaction [1][3]. - Investors can participate online and submit questions in advance from September 5 to September 11, 2025 [2][3]. Group 2: Participants - Key participants include Chairman Li Mingyan, General Manager Li Zhenyu, and other board members [2]. - Adjustments to the participant list may occur due to special circumstances [2]. Group 3: Investor Participation - Investors can log in to the Shanghai Stock Exchange Roadshow Center to join the briefing and ask questions [2][3]. - Questions can be submitted through the website or via email to the company [2][3]. Group 4: Additional Information - After the briefing, investors can view the meeting's details and main content on the Shanghai Stock Exchange Roadshow Center [4].

Group 1 - The company has completed the change of its registered address and the filing of its articles of association, obtaining a new business license from the Guangdong Provincial Market Supervision Administration [1] - The registered address has changed from "Room 3001, 30th Floor, No. 138 Fangyuan Road, Haizhu District, Guangzhou" to "Room 3001, 30th Floor, Yue Media Building, No. 138 Fangyuan Road, Haizhu District, Guangzhou" [1] - The company held meetings on July 30, 2025, and August 15, 2025, to approve the amendment of its articles of association and authorized management to handle related procedures [1] Group 2 - The new business license includes various business activities such as retail of automotive products, investment activities, and digital content production services [2] - The company is involved in sectors including metal materials, electronic components, leather products, textiles, hardware products, and chemical products [2] - The company is permitted to engage in activities that require approval from relevant departments before commencement [2]

Core Viewpoint - The company has successfully acquired land use rights in Shanghai to develop high-quality residential buildings that meet the "good house" standards promoted by the Ministry of Housing and Urban-Rural Development, aligning with national goals for improving construction quality and living standards [1][2]. Group 1: Land Acquisition Details - The company’s subsidiary, Zhejiang Jinggong Steel Structure Group Co., Ltd., has won a bid for a residential land plot in Shanghai, which will be used for developing high-quality residential buildings [1]. - The land was auctioned by the Shanghai Minhang District Planning and Natural Resources Bureau, and there are no related party transactions involved [1]. Group 2: Strategic Impact and Financial Position - The land acquisition allows the company to independently showcase the application of prefabricated construction in the "good house" sector, enhancing the brand's promotion in this field through five key principles: good design, good service, good quality, good construction, and smart buildings [2]. - The funding for the land acquisition and subsequent development will come from the company's own funds, which are currently abundant, ensuring that the financial status and operational results of the company will not be significantly impacted [2].

Core Viewpoint - Nanjing Gaohua Technology Co., Ltd. will hold a semi-annual performance briefing on September 17, 2025, to discuss its operating results and financial status for the first half of 2025, allowing investors to engage in interactive communication [1][2]. Group 1: Meeting Details - The performance briefing is scheduled for September 17, 2025, from 10:00 to 11:00 [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online interactive format [2][3]. - Investors can submit questions from September 10 to September 16, 2025, through the Roadshow Center website or via the company's email [3]. Group 2: Participants - Key participants in the briefing will include Chairman and General Manager Li Weiping, Board Secretary Chen Xin, Chief Financial Officer Li Laiping, and Independent Director Huang Qing'an [2]. Group 3: Investor Participation - Investors can join the performance briefing online on the specified date and time, and the company will address common questions during the session [2][3]. - After the briefing, investors can access the meeting's details and main content through the Roadshow Center [3].

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules, which will enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is classified as a Class 3 chemical drug and is prescribed for patients whose blood pressure is not adequately controlled by Amlodipine or Benazepril alone [1]. - The drug's specifications include 5mg of Amlodipine Besilate and 10mg of Benazepril Hydrochloride per capsule [1]. - The registration certificate number is 2025S02582, and the drug is categorized as a prescription medication [1]. Market Information - The total sales of Amlodipine Besilate and Benazepril Hydrochloride Capsules in China for 2024 are estimated to be approximately 1.12 billion yuan, with sales in urban public hospitals and county-level public hospitals accounting for 727 million yuan [1]. - Sales from urban community centers and township health clinics are projected to be 167 million yuan, while urban pharmacies and online pharmacies are expected to generate 226 million yuan [1]. Company Impact - The approval of the drug registration certificate is expected to enrich the company's product portfolio and improve its market competitiveness [2].

Group 1 - The resignation of non-independent director Wu Binbin was due to work adjustments, and her departure will not affect the board's operation or the company's normal production and operation [1][2] - The board of directors has proposed the nomination of Sun Zhongjun as a candidate for the non-independent director position, which will require approval at the company's second extraordinary general meeting of shareholders in 2025 [2][3] - After the election of the new director, the number of directors who are also senior management will not exceed half of the total number of directors [2] Group 2 - Sun Zhongjun, born in July 1986, holds a bachelor's degree in Human Resource Management from Zhejiang University and has extensive experience in human resources management within various companies [5][6] - Sun Zhongjun does not hold any shares in the company and has no relationships with shareholders holding more than 5% of the company's shares, nor with other directors, supervisors, or senior management [6][7] - Sun Zhongjun meets all legal and regulatory requirements to serve as a director, with no history of administrative penalties or disqualifications from regulatory bodies [6][7]

Core Points - The company will hold a half-year performance briefing on September 12, 2025, from 11:00 to 12:00 [1] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [1] - Investors can submit questions from September 5 to September 11, 2025, via the company's email or the Roadshow Center's website [1] Meeting Details - The meeting is scheduled for September 12, 2025, from 11:00 to 12:00 [1] - Location: Shanghai Stock Exchange Roadshow Center [1] - Format: Online interactive session [1] Participants - Key attendees include the Chairman and General Manager Fang Zhiguang, Secretary of the Board and Financial Officer Luo Xiaoxu, and Independent Director Yu Wei [1] Investor Participation - Investors can join the meeting online on September 12, 2025, and will have the opportunity to ask questions [1] - Questions can be submitted in advance through the Roadshow Center's website or via the company's email [1] Contact Information - Contact person: Jiang Lili, Phone: 021-50818259, Email: info@xf-pharma.com [1] Additional Information - After the briefing, investors can access the meeting details and main content through the Shanghai Stock Exchange Roadshow Center [1]

Core Viewpoint - The company, Shanghai Automotive Air Conditioning Parts Co., Ltd., is holding a half-year performance briefing on September 16, 2025, to discuss its operational results and financial status for the first half of 2025 [1][2]. Group 1: Meeting Details - The meeting is scheduled for September 16, 2025, from 09:00 to 10:00 [1][2]. - It will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [1][2]. - Investors can submit questions from September 9 to September 15, 2025, through the Roadshow Center website or via the company's email [2][3]. Group 2: Participation Information - Company directors and senior management will participate in the meeting, with specific attendees confirmed closer to the date [2]. - Investors can join the meeting online on the specified date and time through the Roadshow Center [2][3]. - After the meeting, investors can access the meeting's main content and outcomes on the Roadshow Center website [3].

Background Overview - Sichuan Road and Bridge Construction Group Co., Ltd. has approved a proposal for its subsidiary to participate in the bidding for the construction project of the Mianyang-Suining section of the Mian-Sui Railway through a fund subscription model [1] - The subsidiary will form a consortium to bid for the project, and upon winning, will subscribe to a private fund designated by the project owner, with the subscription amount being 1/5 of the winning bid [1] Latest Developments - Recently, to ensure the smooth progress of the Mian-Sui project, the subsidiary, Sichuan Railway Construction Co., transferred its subscribed private fund shares worth 781 million yuan to another subsidiary, Sichuan Road and Bridge East China Construction Co., and to Sichuan Transportation Construction Group [2] - The total private fund shares transferred include 547,003,252.20 yuan to East China Construction and 234,024,917.40 yuan to Transportation Construction Group, with the transfer being an internal transaction within the consolidated financial statements of the company [2] Changes in Investment Partners - The change in investment partners does not affect the total investment amount by the company and its subsidiaries, and the matter has been approved by the company's general manager's office without needing further board or shareholder approval [4] - The new partnership agreement maintains the other main terms of the original agreement, with the total subscribed capital amounting to 2,826,350,933 yuan [3] Impact on the Company - The change in the private fund's investment partner is aimed at ensuring the smooth progress of the Mian-Sui project and does not involve adjustments to the total investment amount by the company and its subsidiaries, thus not having a substantial impact on the company [4] - The new partners, East China Construction and Transportation Construction Group, will be liable for the partnership's debts only up to their subscribed capital, indicating that the risks associated with this transaction are manageable [4]